PO.TB09.03 · 肿瘤生物学
单细胞分辨率的全范围基因组分析揭示黑色素瘤亚克隆的遗传、表观遗传及平行进化
Full-range genomic analysis at single-cell resolution reveals genetic, epigenetic, and parallel evolution of melanoma subclones
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
肿瘤进化由多种突变过程驱动,从单核苷酸变异(SNVs)到大型结构变异(SVs),再到DNA甲基化的动态变化。由于固有的技术局限,现有的短读长测序方法难以准确捕获这些基因组和表观基因组改变的完整谱系及其相互关系。在此,我们使用Nanopore长读长测序对23个亚克隆进行分析,每个亚克隆均来源于小鼠黑色素瘤细胞系的单个细胞,从而在亚克隆水平上精确检测并对SNVs、SVs、拷贝数改变(CNAs)和DNA甲基化变化进行进化排序。通过对这些亚克隆的系统发育分析,我们重建了突变过程的时序及其对多样克隆表型的贡献。分析揭示了假定驱动基因的反复扩增,这些扩增由不同谱系中独立发生的SVs所产生,提示存在平行进化。此外,我们描述了与侵袭性肿瘤亚克隆相关的谱系特异性甲基化变化,凸显了与肿瘤进展相关的表观遗传轨迹。总体而言,我们证明我们的长读长方法能够提供对黑色素瘤进展的独特而全面的视角,凸显SVs和甲基化在该肿瘤的起始、克隆多样化及治疗耐药性发展中发挥了重要作用,这与近期的临床发现一致。我们将发布测序数据和经过整理的变异检出结果,以鼓励新的计算方法的开发。
查看英文原文 English abstract
Tumor evolution is driven by various mutational processes, ranging from single nucleotide variants (SNVs) to large structural variants (SVs) to dynamic shifts in DNA methylation. Current short-read sequencing methods struggle to accurately capture the full spectrum of these genomic and epigenomic alterations, as well as their relations, due to inherent technical limitations. Here we used Nanopore long-read sequencing to profile 23 subclones, each derived from a single cell of a mouse melanoma cell line, for precise detection and evolutionary ordering of SNVs, SVs, copy number alterations (CNAs), and DNA methylation changes at subclonal level. Through phylogenetic analysis of these subclones, we reconstruct the timing of mutational processes and their contributions to diverse clonal phenotypes. The analysis reveals recurrent amplifications of putative driver genes, generated by independent SVs across different lineages, suggesting parallel evolution. Additionally, we described lineage-specific methylation changes associated with aggressive tumor subclones, highlighting epigenetic trajectories linked to tumor progression. Overall, we demonstrate that our long-read approach enables a uniquely comprehensive view of melanoma progression, highlighting that SVs and methylation played an important role in initiation, clonal diversification, and development of therapeutic resistance in this tumor, in consistence with recent clinical findings. We will release the sequencing data and curated variant calls to encourage developments of new computational methods.
利益披露 Disclosure
C. Day, None..
Y. Liu, None..
A. Goretsky, None..
A. Keskus, None..
S. Malikic, None..
E. Perez-Guijarro, None..
G. Merlino, None..
E. Ruppin, None..
S. Sahinalp, None..
M. Kolmogorov, None.